CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

What happened

CEL-SCI presented new Phase 3 data on Multikine for head and neck cancer, showing 73.4% five-year overall survival with Multikine plus standard of care versus 45.0% with standard of care alone in a biomarker-identified patient group.

Confirmed

Global impact / market context

If these results hold in the planned U.S. registration study, Multikine could become a pre-surgery treatment for selected patients. That would give CEL-SCI a potential new product and revenue path in head and neck cancer.

Analyst inference

The data support CEL-SCI's push toward a U.S. registration trial, a key step before regulatory review. Investors often treat such trial plans as high-risk because success depends on confirming survival benefits in a larger patient group.

Analyst inference

What to watch

1. CEL-SCI says the findings are the scientific foundation for its upcoming Phase 3 U.S. Registration Study of Multikine, a trial intended to support regulatory review. Confirmed
2. Watch whether CEL-SCI discloses the registration study's design, including patient selection by pre-surgical biomarkers, enrollment size, and timeline, which shape cost and risk. Proposed
3. Track any regulatory feedback on using biomarkers to select patients, since acceptance could affect trial costs, approval odds, and how investors value CEL-SCI's pipeline. Analyst inference

Evidence

• Original source link unavailable